BRIEF—Biogen broadens label for Plegridy

Biogen has won European approval for a new intramuscular (IM) injection route of administration for Plegridy (peginterferon beta-1a) in relapsing-remitting multiple sclerosis (MS).

The decision extends Biogen’s broad MS portfolio which includes the subcutaneous (SC) injection of Plegridy.

Plegridy, the only pegylated interferon approved for use in relapsing MS, was first approved in the European Union in 2014.

Biogen has also submitted a regulatory filing in the USA for the IM administration.